Literature DB >> 17035346

Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming.

Dietmar Zehn1, Cyril J Cohen, Yoram Reiter, Peter Walden.   

Abstract

Dendritic cells (DCs) play a key role in the induction of cellular immune responses by harvesting antigens from peripheral tissue for cross-priming CD8(+) T cells. It has been demonstrated that apoptotic bodies, whole- or degraded-cell-associated or soluble antigens as well as heat shock protein-bound peptides can be taken up, processed and cross-presented by DCs. Since cells are continuously releasing peptides from their surface MHC molecules, DCs in the tissues are exposed to such peptides and might process and present them to T cells as an additional pathway for cross-priming. To investigate this possibility, we compared and characterized the presentation of exogenous peptides by DCs and other cell types employing novel recombinant antibodies with TCR-like specificities for specific peptide-MHC complexes (pMHCs). These analyses reveal that loading of immature and mature DCs with peptide is far less efficient than it is for monocytes, T and B lymphocytes, B-lymphoblastoid, melanoma and TAP-deficient T2 cells. This inefficiency of peptide transfer to the MHC molecules of DCs makes it unlikely that these cells recycle peptides released from the MHC molecules of other cells and may explain why cross-presentation of such peptides has not yet been observed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035346     DOI: 10.1093/intimm/dxl098

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.

Authors:  Samudra K Dissanayake; Purevdorj B Olkhanud; Michael P O'Connell; Arnell Carter; Amanda D French; Tura C Camilli; Chineye D Emeche; Kyle J Hewitt; Devin T Rosenthal; Poloko D Leotlela; Michael S Wade; Sherry W Yang; Larry Brant; Brian J Nickoloff; Jane L Messina; Arya Biragyn; Keith S Hoek; Dennis D Taub; Dan L Longo; Vernon K Sondak; Stephen M Hewitt; Ashani T Weeraratna
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

2.  An in silico model of cytotoxic T-lymphocyte activation in the lymph node following short peptide vaccination.

Authors:  Liam V Brown; Eamonn A Gaffney; Jonathan Wagg; Mark C Coles
Journal:  J R Soc Interface       Date:  2018-03       Impact factor: 4.118

3.  Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells.

Authors:  Xiao-Li Huang; Zheng Fan; Luann Borowski; Charles R Rinaldo
Journal:  Clin Vaccine Immunol       Date:  2009-08-19

4.  Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late.

Authors:  Saghar Kaabinejadian; Curtis P McMurtrey; Sojung Kim; Rinki Jain; Wilfried Bardet; Fredda B Schafer; Jason L Davenport; Aaron D Martin; Michael S Diamond; Jon A Weidanz; Ted H Hansen; William H Hildebrand
Journal:  J Immunol       Date:  2016-04-20       Impact factor: 5.422

5.  Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo.

Authors:  Peng Wang; Shuyun Dong; Peng Zhao; Xiao He; Mingnan Chen
Journal:  Biomaterials       Date:  2018-08-06       Impact factor: 12.479

6.  A tissue-like platform for studying engineered quiescent human T-cells' interactions with dendritic cells.

Authors:  Philippos Demetriou; Štefan Bálint; Enas Abu-Shah; Viveka Mayya; Mikhail A Kutuzov; Omer Dushek; Michael L Dustin
Journal:  Elife       Date:  2019-09-25       Impact factor: 8.713

7.  Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Authors:  Sue Ellen Verbrugge; Marjon Al; Yehuda G Assaraf; Denise Niewerth; Johan van Meerloo; Jacqueline Cloos; Michael van der Veer; George L Scheffer; Godefridus J Peters; Elena T Chan; Janet L Anderl; Christopher J Kirk; Sonja Zweegman; Ben Ac Dijkmans; Willem F Lems; Rik J Scheper; Tanja D de Gruijl; Gerrit Jansen
Journal:  Exp Hematol Oncol       Date:  2013-01-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.